(Alliance News) - Drug consulting platform Open Orphan PLC said on Thursday that it has appointed David Kelly as an independent non-executive director.
Kelly, the company said, has "extensive" orphan drug company experience both in Europe and in the US. Kelly was formerly at AGI Therapeutics PLC and helped in "turning around" the company before it was sold to Horizon Therapeutics PLC, where he was once managing director.
Shares in Open Orphan closed 0.8% lower at 6.60 pence each in London on Thursday.
